AZD1222 US Phase III primary analysis confirms safety and efficacy
The Pharma Data
MARCH 24, 2021
76% vaccine efficacy against symptomatic COVID-19. Positive high-level results from the primary analysis of the Phase III trial of AZD1222 in the US have confirmed vaccine efficacy consistent with the pre-specified interim analysis announced on Monday 22 March 2021. 100% efficacy against severe or critical disease and hospitalisation.
Let's personalize your content